Jiacheng Dong, Jiayue Cui, Ying Guo, Shaohua Wang, Wenhui Liu, Xinyu Hong
Department of Neurosurgery, Jilin Provincial Hospital, The First Hospital of Jilin University, 1 Xinmin Street, Changchun, Jilin, 130021, China.
Department of Histology and Embryology, The School of Basic Medicine, Jilin University, 126 Xinmin Street, Changchun, Jilin, 130021, China.
Cell Biosci. 2024 Sep 27;14(1):123. doi: 10.1186/s13578-024-01305-6.
The emergence of programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) immunosuppressants provides new therapeutic directions for various advanced malignant cancers. At present, PD-1/PD-L1 immunosuppressants have made significant progress in clinical trials of some gliomas, but PD-1/PD-L1 inhibitors have not yet shown convincing clinical efficacy in gliomas. This article summarizes the research progress of the PD-1 /PD-L1 pathway in gliomas through the following three aspects. It mainly includes the complex expression levels and regulatory mechanisms of PD-1/PD-L1 in the glioma microenvironment, the immune infiltration in glioma immunosuppressive microenvironment, and research progress on the application of PD-1/PD-L1 immunosuppressants in clinical treatment trials for gliomas. This will help to understand the current treatment progress and future research directions better.
程序性死亡蛋白1（PD-1）和程序性死亡配体1（PD-L1）免疫抑制剂的出现为各种晚期恶性肿瘤提供了新的治疗方向。目前，PD-1/PD-L1免疫抑制剂在一些胶质瘤的临床试验中取得了显著进展，但PD-1/PD-L1抑制剂在胶质瘤中尚未显示出令人信服的临床疗效。本文通过以下三个方面总结了PD-1/PD-L1通路在胶质瘤中的研究进展。主要包括PD-1/PD-L1在胶质瘤微环境中的复杂表达水平及调控机制、胶质瘤免疫抑制微环境中的免疫浸润，以及PD-1/PD-L1免疫抑制剂在胶质瘤临床治疗试验中的应用研究进展。这将有助于更好地了解当前的治疗进展和未来的研究方向。
Zotero 插件